Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Kekkaku : [Tuberculosis]|October 23, 2015
[A TUBERCULOUS PSEUDO-ANEURYSM OF THE ABDOMINAL AORTA COMPLICATED BY MILIARY TUBERCULOSIS]Toyoshi Matsutake, Kouji Hashizume, Naoe Kinoshita, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|January 19, 2016
A novel method for rapid detection of Streptococcus pneumoniae antigens in bloodKiyoyasu Fukushima, Toru Kubo, Naomi Ehara, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic informationChangying Li, Matthew R Buckwalter, Sreyashi Basu, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2017
Endocannabinoid system acts as a regulator of immune homeostasis in the gutNandini Acharya, Sasi Penukonda, Tatiana Shcheglova, et al.
Thoracic Cancer|November 5, 2023
TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case reportFumiko Hayashi, Kazumasa Akagi, Hirokazu Taniguchi, et al.
Cancer Cell|March 15, 2022
A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse eventsSangeeta Goswami, Bilal A Siddiqui, Sumit K Subudhi, et al.
Science Advances|September 10, 2025
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapyJielin Liu, Shelley Herbrich, Sreyashi Basu, et al.
Kidney International Reports|January 16, 2026
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational EvidenceNada Youssef, Masroor Habeeb, Hong Chen, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinomaZhenqin Wu, Joseph Boen, Sonali Jindal, et al.
Oncotarget|March 19, 2024
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancerHaven R Garber, Sreyashi Basu, Sonali Jindal, et al.
Pageof 6